Gulf Pharmaceutical Industries

JULPHAR

AEG000201018

Pharmaceuticals

Market Closed - Abu Dhabi Securities Exchange Other stock markets 04:11:48 28/05/2024 pm IST			5-day change	1st Jan Change
0.88 ^AED	-1.23%		-5.58%	+14.43%

15/05	Julphar Resumes Trading on Abu Dhabi Bourse	MT
15/05	Gulf Pharmaceutical Industries Turns to Q1 Profit; Revenue Tumbles	MT

Gulf Pharmaceutical Industries Appoints Jerome Carle as Acting General Manger; Proposes Cash Dividend for 2016

March 19, 2017

Gulf Pharmaceutical Industries announced that at the board of directors meeting held on March 19,2017, the company appointed Mr. Jerome Carle as Acting General manager until appointment of new GM from April 20,2017.

The company also proposed 16% cash dividend for the 2016.

Latest news about Gulf Pharmaceutical Industries

Julphar Resumes Trading on Abu Dhabi Bourse	15/05	MT
Gulf Pharmaceutical Industries Turns to Q1 Profit; Revenue Tumbles	15/05	MT
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Gulf Pharmaceutical Industries to Temporarily Halt Trading in Abu Dhabi on May 14	09/05	MT
Gulf Pharmaceutical Industries Shares to be Suspended Ahead of Annual General Meeting	21/03	MT
Abu Dhabi's Gulf Pharmaceutical Industries Resumes Trading Following FY23 Results Publication	15/03	MT
Gulf Pharmaceutical Industries' FY23 Attributable Loss Widens; Revenue Up	15/03	MT
Gulf Pharmaceutical Industries to Halt Trading During Board Meeting	11/03	MT
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2023	13/02	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Gulf Pharmaceutical Industries P.S.C. Approves Board Appointments	14/23/14	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes	15/23/15	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09	CI
Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer	11/22/11	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/22/11	CI
Cigalah Group completed the acquisition of 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C..	19/22/19	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2021	18/22/18	CI
Gulf Pharmaceutical Industries Announces the Resignation of Ragheb Alshakhshir as Chief Scientific Officer	01/22/01	CI
Quantum Genomics Société Anonyme Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar	06/21/06	CI
Quantum Genomics Société Anonyme announced that it expects to receive $2 million in funding from Gulf Pharmaceutical Industries P.S.C.	06/21/06	CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	11/21/11	CI

Chart Gulf Pharmaceutical Industries

Duration

Period

More charts

Company Profile

Gulf Pharmaceutical Industries PSC (Julphar) is a United Arab Emirates-based public shareholding company engaged in manufacturing and selling of medicines, drugs and other types of pharmaceutical and medical compounds, in addition to cosmetic compounds. The Company maintains a range of product portfolio, which target major therapeutic segments, including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management. The Company operates through a network of more than 10 manufacturing plants, and a logistics network. The Company has approximately 800 products in various dosage forms, and more in the pipeline. The Companyâs subsidiaries include Mena Cool FZE, which is engaged in the transportation, and Julphar Pharmaceuticals PLC, which is engaged in Manufacturing of medicines, wrapping and packing materials.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Gulf Pharmaceutical Industries

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.88 AED

Average target price

0.72 AED

Spread / Average Target

-18.18%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
GULF PHARMACEUTICAL INDUSTRIES	+14.43%	28Cr
MERCK KGAA	+16.34%	7.9TCr
KYOWA KIRIN CO. LTD.	+8.31%	877.86Cr
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	482.95Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.22%	465.14Cr
YUHAN CORPORATION	+2.18%	389.22Cr
INDIVIOR PLC	+20.51%	233.76Cr
BETTA PHARMACEUTICALS CO., LTD.	-26.79%	217.56Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.12%	211.24Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.56%	199.51Cr

Specialty & Advanced Pharmaceuticals